Regulatory T Cells and Tumour Immunotherapy



Immune responses influence the development and progression of a malignancy. However, the tumor can manipulate the immune system on its own end, often resulting in an ineffective tumor immunity and immune suppression, ablating the clinical efficacy of tumor therapy. An appreciation of the complexity of the interaction between tumor and host immune system is important for the development of effective cancer therapies. The chapter will emphasize regulatory T cells as a prominent mechanism whereby tumors escape tumor immunity and highlight the newly therapeutic strategies by targeting Treg cells in patients with cancer.


Treg Cell Suppressive Activity Tumor Immunity Dendritic Cell Vaccination Objective Clinical Response 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Gershon, R.K. and K. Kondo, Cell interactions in the induction of tolerance: the role of thymic lymphocytes. Immunology, 1970, 18(5): 723–37.PubMedGoogle Scholar
  2. 2.
    Sakaguchi, S., et al., Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol, 1995, 155(3): 1151–64.PubMedGoogle Scholar
  3. 3.
    Suri-Payer, E., et al., CD4+CD25+ T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells. J Immunol, 1998, 160(3): 1212–8.PubMedGoogle Scholar
  4. 4.
    Thornton, A.M. and E.M. Shevach, CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med, 1998, 188(2): 287–96.PubMedCrossRefGoogle Scholar
  5. 5.
    Berendt, M.J. and R.J. North, T-cell-mediated suppression of anti-tumor immunity. An explanation for progressive growth of an immunogenic tumor. J Exp Med, 1980, 151(1): 69–80.PubMedCrossRefGoogle Scholar
  6. 6.
    Bursuker, I. and R.J. North, Generation and decay of the immune response to a progressive fibrosarcoma. II. Failure to demonstrate postexcision immunity after the onset of T cell-mediated suppression of immunity. J Exp Med, 1984, 159(5): 1312–21.PubMedCrossRefGoogle Scholar
  7. 7.
    North, R.J. and I. Bursuker, Generation and decay of the immune response to a progressive fibrosarcoma. I. Ly-1+2- suppressor T cells down-regulate the generation of Ly-1-2+ effector T cells. J Exp Med, 1984, 159(5): 1295–311.PubMedCrossRefGoogle Scholar
  8. 8.
    Onizuka, S., et al., Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res, 1999, 59(13): 3128–33.PubMedGoogle Scholar
  9. 9.
    Sakaguchi, S., Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol, 2005, 6(4): 345–52.PubMedCrossRefGoogle Scholar
  10. 10.
    Curiel, T.J., et al., Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med, 2004, 10(9): 942–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Woo, E.Y., et al., Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res, 2001, 61(12): 4766–72.PubMedGoogle Scholar
  12. 12.
    Ishibashi, Y., et al., Expression of Foxp3 in non-small cell lung cancer patients is significantly higher in tumor tissues than in normal tissues, especially in tumors smaller than 30 mm. Oncol Rep, 2006, 15(5): 1315–9.PubMedGoogle Scholar
  13. 13.
    Sasada, T., et al., CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer, 2003, 98(5): 1089–99.PubMedCrossRefGoogle Scholar
  14. 14.
    Liyanage, U.K., et al., Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol, 2002, 169(5): 2756–61.PubMedGoogle Scholar
  15. 15.
    Appay, V., et al., New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site. J Immunol, 2006, 177(3): 1670–8.PubMedGoogle Scholar
  16. 16.
    Ishida, T., et al., Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege. Cancer Res, 2006, 66(11): 5716–22.PubMedCrossRefGoogle Scholar
  17. 17.
    Yang, Z.Z., et al., Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma. Blood, 2006, 107(9): 3639–46.PubMedCrossRefGoogle Scholar
  18. 18.
    Meloni, F., et al., Foxp3 expressing CD4+ CD25+ and CD8+CD28- T regulatory cells in the peripheral blood of patients with lung cancer and pleural mesothelioma. Hum Immunol, 2006, 67(1–2): 1–12.PubMedCrossRefGoogle Scholar
  19. 19.
    Ormandy, L.A., et al., Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res, 2005, 65(6): 2457–64.PubMedCrossRefGoogle Scholar
  20. 20.
    Lau, K.M., et al., Increase in circulating Foxp3+CD4+CD25(high) regulatory T cells in nasopharyngeal carcinoma patients. Br J Cancer, 2007, 96(4): 617–22.PubMedCrossRefGoogle Scholar
  21. 21.
    Zou, W., Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer, 2005, 5(4): 263–74.PubMedCrossRefGoogle Scholar
  22. 22.
    Zou, W., Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol, 2006, 6(4): 295–307.PubMedCrossRefGoogle Scholar
  23. 23.
    Shimizu, J., S. Yamazaki, and S. Sakaguchi, Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol, 1999, 163(10): 5211–8.PubMedGoogle Scholar
  24. 24.
    Jones, E., et al., Depletion of CD25+ regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice. Cancer Immun, 2002, 2: 1.PubMedGoogle Scholar
  25. 25.
    Ko, K., et al., Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells. J Exp Med, 2005, 202(7): 885–91.PubMedCrossRefGoogle Scholar
  26. 26.
    Casares, N., et al., CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination. J Immunol, 2003, 171(11): 5931–9.PubMedGoogle Scholar
  27. 27.
    Foss, F.M., DAB(389)IL-2 (denileukin diftitox, ONTAK): a new fusion protein technology. Clin Lymphoma, 2000, 1(Suppl 1): S27–31.PubMedCrossRefGoogle Scholar
  28. 28.
    Foss, F.M., DAB(389)IL-2 (ONTAK): a novel fusion toxin therapy for lymphoma. Clin Lymphoma, 2000, 1(2): 110–6; discussion 117.PubMedCrossRefGoogle Scholar
  29. 29.
    Dannull, J., et al., Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest, 2005, 115(12): 3623–33.PubMedCrossRefGoogle Scholar
  30. 30.
    Barnett, B., et al., Regulatory T cells in ovarian cancer: biology and therapeutic potential. Am J Reprod Immunol, 2005, 54(6): 369–77.PubMedCrossRefGoogle Scholar
  31. 31.
    Attia, P., et al., Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. J Immunother, 2005, 28(6): 582–92.PubMedCrossRefGoogle Scholar
  32. 32.
    Liu, W., et al., CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med, 2006, 203(7): 1701–11.PubMedCrossRefGoogle Scholar
  33. 33.
    Collins, A.V., et al., The interaction properties of costimulatory molecules revisited. Immunity, 2002, 17(2): 201–10.PubMedCrossRefGoogle Scholar
  34. 34.
    Walunas, T.L., et al., CTLA-4 can function as a negative regulator of T cell activation. Immunity, 1994, 1(5): 405–13.PubMedCrossRefGoogle Scholar
  35. 35.
    Krummel, M.F. and J.P. Allison, CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med, 1995, 182(2): 459–65.PubMedCrossRefGoogle Scholar
  36. 36.
    Waterhouse, P., et al., Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science, 1995, 270(5238): 985–8.PubMedCrossRefGoogle Scholar
  37. 37.
    Kulkarni, A.B., et al., Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci USA, 1993, 90(2): 770–4.PubMedCrossRefGoogle Scholar
  38. 38.
    Tivol, E.A., et al., Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity, 1995, 3(5): 541–7.PubMedCrossRefGoogle Scholar
  39. 39.
    Ueda, H., et al., Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature, 2003, 423(6939): 506–11.PubMedCrossRefGoogle Scholar
  40. 40.
    Sansom, D.M. and L.S. Walker, The role of CD28 and cytotoxic T-lymphocyte antigen-4 (CTLA-4) in regulatory T-cell biology. Immunol Rev, 2006, 212: 131–48.PubMedCrossRefGoogle Scholar
  41. 41.
    Read, S., V. Malmstrom, and F. Powrie, Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med, 2000, 192(2): 295–302.PubMedCrossRefGoogle Scholar
  42. 42.
    Takahashi, T., et al., Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med, 2000, 192(2): 303–10.PubMedCrossRefGoogle Scholar
  43. 43.
    Phan, G.Q., et al., Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA, 2003, 100(14): 8372–7.PubMedCrossRefGoogle Scholar
  44. 44.
    Sanderson, K., et al., Autoimmunity in a phase I trial of a fully human anti-cytotoxicT-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol, 2005, 23(4): 741–50.PubMedCrossRefGoogle Scholar
  45. 45.
    Attia, P., et al., Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol, 2005, 23(25): 6043–53.PubMedCrossRefGoogle Scholar
  46. 46.
    Maker, A.V., et al., Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J Immunother, 2006, 29(4): 455–63.PubMedCrossRefGoogle Scholar
  47. 47.
    Maker, A.V., P. Attia, and S.A. Rosenberg, Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J Immunol, 2005, 175(11): 7746–54.PubMedGoogle Scholar
  48. 48.
    Levings, M.K., R. Sangregorio, and M.G. Roncarolo, Human cd25(+)cd4(+) t regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J Exp Med, 2001, 193(11): 1295–302.PubMedCrossRefGoogle Scholar
  49. 49.
    Jonuleit, H., et al., Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood. J Exp Med, 2001, 193(11): 1285–94.PubMedCrossRefGoogle Scholar
  50. 50.
    Baecher-Allan, C., et al., CD4+CD25+ regulatory cells from human peripheral blood express very high levels of CD25 ex vivo. Novartis Found Symp, 2003, 252: 67–88; discussion 88–91, 106–14.PubMedCrossRefGoogle Scholar
  51. 51.
    Ng, W.F., et al., Human CD4(+)CD25(+) cells: a naturally occurring population of regulatory T cells. Blood, 2001, 98(9): 2736–44.PubMedCrossRefGoogle Scholar
  52. 52.
    Liu, H., et al., CD4+CD25+ regulatory T cells cure murine colitis: the role of IL-10, TGF-beta, and CTLA4. J Immunol, 2003, 171(10): 5012–7.PubMedGoogle Scholar
  53. 53.
    Salomon, B., et al., B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity, 2000, 12(4): 431–40.PubMedCrossRefGoogle Scholar
  54. 54.
    Read, S., et al., Blockade of CTLA-4 on CD4+CD25+ regulatory T cells abrogates their function in vivo. J Immunol, 2006, 177(7): 4376–83.PubMedGoogle Scholar
  55. 55.
    Chen, W., W. Jin, and S.M. Wahl, Engagement of cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) induces transforming growth factor beta (TGF-beta) production by murine CD4(+) T cells. J Exp Med, 1998, 188(10): 1849–57.PubMedCrossRefGoogle Scholar
  56. 56.
    McHugh, R.S., et al., CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity, 2002, 16(2): 311–23.PubMedCrossRefGoogle Scholar
  57. 57.
    Shimizu, J., et al., Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol, 2002, 3(2): 135–42.PubMedCrossRefGoogle Scholar
  58. 58.
    Kanamaru, F., et al., Costimulation via glucocorticoid-induced TNF receptor in both conventional and CD25+ regulatory CD4+ T cells. J Immunol, 2004, 172(12): 7306–14.PubMedGoogle Scholar
  59. 59.
    Shevach, E.M. and G.L. Stephens, The GITR-GITRL interaction: co-stimulation or contrasuppression of regulatory activity? Nat Rev Immunol, 2006, 6(8): 613–8.PubMedCrossRefGoogle Scholar
  60. 60.
    Kohm, A.P., J.S. Williams, and S.D. Miller, Cutting edge: ligation of the glucocorticoid-induced TNF receptor enhances autoreactive CD4+ T cell activation and experimental autoimmune encephalomyelitis. J Immunol, 2004, 172(8): 4686–90.PubMedGoogle Scholar
  61. 61.
    Stephens, G.L., et al., Engagement of glucocorticoid-induced TNFR family-related receptor on effector T cells by its ligand mediates resistance to suppression by CD4+CD25+ T cells. J Immunol, 2004, 173(8): 5008–20.PubMedGoogle Scholar
  62. 62.
    Turk, M.J., et al., Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med, 2004, 200(6): 771–82.PubMedCrossRefGoogle Scholar
  63. 63.
    Ronchetti, S., et al., GITR, a member of the TNF receptor superfamily, is costimulatory to mouse T lymphocyte subpopulations. Eur J Immunol, 2004, 34(3): 613–22.PubMedCrossRefGoogle Scholar
  64. 64.
    Wu, Y., et al., FOXP3 controls regulatory T cell function through cooperation with NFAT. Cell, 2006, 126(2): 375–87.PubMedCrossRefGoogle Scholar
  65. 65.
    Chen, C., et al., Transcriptional regulation by Foxp3 is associated with direct promoter occupancy and modulation of histone acetylation. J Biol Chem, 2006, 281(48): 36828–34.PubMedCrossRefGoogle Scholar
  66. 66.
    Bettelli, E., M. Dastrange, and M. Oukka, Foxp3 interacts with nuclear factor of activated T cells and NF-kappa B to repress cytokine gene expression and effector functions of T helper cells. Proc Natl Acad Sci USA, 2005, 102(14): 5138–43.PubMedCrossRefGoogle Scholar
  67. 67.
    Loh, C., et al., Calcineurin binds the transcription factor NFAT1 and reversibly regulates its activity. J Biol Chem, 1996, 271(18): 10884–91.PubMedCrossRefGoogle Scholar
  68. 68.
    Ho, S., et al., The mechanism of action of cyclosporin A and FK506. Clin Immunol Immunopathol, 1996, 80(3 Pt 2): S40–5.PubMedCrossRefGoogle Scholar
  69. 69.
    Awwad, M. and R.J. North, Cyclophosphamide (Cy)-facilitated adoptive immunotherapy of a Cy-resistant tumour. Evidence that Cy permits the expression of adoptive T-cell mediated immunity by removing suppressor T cells rather than by reducing tumour burden. Immunology, 1988, 65(1): 87–92.PubMedGoogle Scholar
  70. 70.
    Ghiringhelli, F., et al., CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol, 2004, 34(2): 336–44.PubMedCrossRefGoogle Scholar
  71. 71.
    Lutsiak, M.E., et al., Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood, 2005, 105(7): 2862–8.PubMedCrossRefGoogle Scholar
  72. 72.
    Caproni, M., et al., The effects of tacrolimus ointment on regulatory T lymphocytes in atopic dermatitis. J Clin Immunol, 2006, 26(4): 370–5.PubMedCrossRefGoogle Scholar
  73. 73.
    San Segundo, D., et al., Calcineurin inhibitors affect circulating regulatory T cells in stable renal transplant recipients. Transplant Proc, 2006, 38(8): 2391–3.PubMedCrossRefGoogle Scholar
  74. 74.
    Frank, D.A., S. Mahajan, and J. Ritz, Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling. Nat Med, 1999, 5(4): 444–7.PubMedCrossRefGoogle Scholar
  75. 75.
    Nishibori, T., et al., Impaired development of CD4+ CD25+ regulatory T cells in the absence of STAT1: increased susceptibility to autoimmune disease. J Exp Med, 2004, 199(1): 25–34.PubMedCrossRefGoogle Scholar
  76. 76.
    Beyer, M., et al., Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood, 2005, 106(6): 2018–25.PubMedCrossRefGoogle Scholar
  77. 77.
    Baecher-Allan, C., et al., CD4+CD25high regulatory cells in human peripheral blood. J Immunol, 2001, 167(3): 1245–53.PubMedGoogle Scholar
  78. 78.
    Hoffmann, P., et al., Large-scale in vitro expansion of polyclonal human CD4(+)CD25high regulatory T cells. Blood, 2004, 104(3): 895–903.PubMedCrossRefGoogle Scholar
  79. 79.
    Cavani, A., et al., Human CD25+ regulatory T cells maintain immune tolerance to nickel in healthy, nonallergic individuals. J Immunol, 2003, 171(11): 5760–8.PubMedGoogle Scholar
  80. 80.
    Iellem, A., et al., Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4(+)CD25(+) regulatory T cells. J Exp Med, 2001, 194(6): 847–53.PubMedCrossRefGoogle Scholar
  81. 81.
    Iellem, A., L. Colantonio, and D. D'Ambrosio, Skin-versus gut-skewed homing receptor expression and intrinsic CCR4 expression on human peripheral blood CD4+CD25+ suppressor T cells. Eur J Immunol, 2003, 33(6): 1488–96.PubMedCrossRefGoogle Scholar
  82. 82.
    Stassen, M., et al., Human CD25+ regulatory T cells: two subsets defined by the integrins alpha 4 beta 7 or alpha 4 beta 1 confer distinct suppressive properties upon CD4+ T helper cells. Eur J Immunol, 2004, 34(5): 1303–11.PubMedCrossRefGoogle Scholar
  83. 83.
    Allakhverdi, Z., et al., Expression of CD103 identifies human regulatory T-cell subsets. J Allergy Clin Immunol, 2006, 118(6): 1342–9.PubMedCrossRefGoogle Scholar
  84. 84.
    Chen, X., et al., Pertussis toxin as an adjuvant suppresses the number and function of CD4+CD25+ T regulatory cells. Eur J Immunol, 2006, 36(3): 671–80.PubMedCrossRefGoogle Scholar
  85. 85.
    Hultkrantz, S., S. Ostman, and E. Telemo, Induction of antigen-specific regulatory T cells in the liver-draining celiac lymph node following oral antigen administration. Immunology, 2005, 116(3): 362–72.PubMedCrossRefGoogle Scholar
  86. 86.
    Wei, S., I. Kryczek, and W. Zou, Regulatory T-cell compartmentalization and trafficking. Blood, 2006, 108(2): 426–31.PubMedCrossRefGoogle Scholar
  87. 87.
    Zou, L., et al., Bone marrow is a reservoir for CD4+CD25+ regulatory T cells that traffic through CXCL12/CXCR4 signals. Cancer Res, 2004, 64(22): 8451–5.PubMedCrossRefGoogle Scholar
  88. 88.
    Kryczek, I., et al., Cutting edge: induction of B7-H4 on APCs through IL-10: novel suppressive mode for regulatory T cells. J Immunol, 2006, 177(1): 40–4.PubMedGoogle Scholar
  89. 89.
    Schramm, C., et al., TGFbeta regulates the CD4+CD25+ T-cell pool and the expression of Foxp3 in vivo. Int Immunol, 2004, 16(9): 1241–9.PubMedCrossRefGoogle Scholar
  90. 90.
    Chen, W., et al., Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med, 2003, 198(12): 1875–86.PubMedCrossRefGoogle Scholar
  91. 91.
    Walker, M.R., et al., Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25- T cells. J Clin Invest, 2003, 112(9): 1437–43.PubMedGoogle Scholar
  92. 92.
    Walker, M.R., et al., De novo generation of antigen-specific CD4+CD25+ regulatory T cells from human CD4+CD25- cells. Proc Natl Acad Sci USA, 2005, 102(11): 4103–8.PubMedCrossRefGoogle Scholar
  93. 93.
    Morgan, M.E., et al., Expression of FOXP3 mRNA is not confined to CD4+CD25+ T regulatory cells in humans. Hum Immunol, 2005, 66(1): 13–20.PubMedCrossRefGoogle Scholar
  94. 94.
    Curotto de Lafaille, M.A., et al., CD25- T cells generate CD25+Foxp3+ regulatory T cells by peripheral expansion. J Immunol, 2004, 173(12): 7259–68.PubMedGoogle Scholar
  95. 95.
    Liang, S., et al., Conversion of CD4+ CD25- cells into CD4+ CD25+ regulatory T cells in vivo requires B7 costimulation, but not the thymus. J Exp Med, 2005, 201(1): 127–37.PubMedCrossRefGoogle Scholar
  96. 96.
    Apostolou, I. and H. von Boehmer, In vivo instruction of suppressor commitment in naive T cells. J Exp Med, 2004, 199(10): 1401–8.PubMedCrossRefGoogle Scholar
  97. 97.
    von Boehmer, H., Peptide-based instruction of suppressor commitment in naive T cells and dynamics of immunosuppression in vivo. Scand J Immunol, 2005, 62(Suppl 1): 49–54.CrossRefGoogle Scholar
  98. 98.
    Knoechel, B., et al., Sequential development of interleukin 2-dependent effector and regulatory T cells in response to endogenous systemic antigen. J Exp Med, 2005, 202(10): 1375–86.PubMedCrossRefGoogle Scholar
  99. 99.
    Kretschmer, K., et al., Inducing and expanding regulatory T cell populations by foreign antigen. Nat Immunol, 2005, 6(12): 1219–27.PubMedCrossRefGoogle Scholar
  100. 100.
    Ghiringhelli, F., et al., Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J Exp Med, 2005, 202(7): 919–29.PubMedCrossRefGoogle Scholar
  101. 101.
    Zhou, G. and H.I. Levitsky, Natural regulatory T cells and de novo-induced regulatory T cells contribute independently to tumor-specific tolerance. J Immunol, 2007, 178(4): 2155–62.PubMedGoogle Scholar
  102. 102.
    Nakamura, K., et al., TGF-beta 1 plays an important role in the mechanism of CD4+CD25+ regulatory T cell activity in both humans and mice. J Immunol, 2004, 172(2): 834–42.PubMedGoogle Scholar
  103. 103.
    Ghiringhelli, F., et al., CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med, 2005, 202(8): 1075–85.PubMedCrossRefGoogle Scholar
  104. 104.
    Liu, V.C., et al., Tumor evasion of the immune system by converting CD4+CD25- T cells into CD4+CD25+ T regulatory cells: role of tumor-derived TGF-beta. J Immunol, 2007, 178(5): 2883–92.PubMedGoogle Scholar
  105. 105.
    Schlingensiepen, K.H., et al., Targeted tumor therapy with the TGF-beta2 antisense compound AP 12009. Cytokine Growth Factor Rev, 2006, 17(1–2): 129–39.Google Scholar
  106. 106.
    Fakhrai, H., et al., Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy. Proc Natl Acad Sci USA, 1996, 93(7): 2909–14.PubMedCrossRefGoogle Scholar
  107. 107.
    Fakhrai, H., et al., Phase I clinical trial of a TGF-beta antisense-modified tumor cell vaccine in patients with advanced glioma. Cancer Gene Ther, 2006, 13(12): 1052–60.PubMedCrossRefGoogle Scholar
  108. 108.
    Reuben, J.M., et al., Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma. Cancer, 2006, 106(11): 2437–44.PubMedCrossRefGoogle Scholar
  109. 109.
    Maker, A.V., et al., Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol, 2005, 12(12): 1005–16.PubMedCrossRefGoogle Scholar
  110. 110.
    Blansfield, J.A., et al., Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother, 2005, 28(6): 593–8.PubMedCrossRefGoogle Scholar
  111. 111.
    Hodi, F.S., et al., Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA, 2003, 100(8): 4712–7.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  1. 1.Department of SurgeryUniversity of Michigan School of Medicine1150 W. Medical Center Dr. Ann ArborUSA

Personalised recommendations